A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
about
CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytesEndothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in miceThe fungal pattern recognition receptor, Dectin-1, and the associated cluster of C-type lectin-like receptorsCrystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by plateletsAn EF hand mutation in Stim1 causes premature platelet activation and bleeding in miceMolecular underpinnings of corneal angiogenesis: advances over the past decadeThe role of platelets in the recruitment of leukocytes during vascular diseaseInflammation and vascular injury: basic discovery to drug developmentRegulation of platelet plug formation by phosphoinositide metabolismPlatelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling.New horizon in platelet function: with special reference to a recently-found molecule, CLEC-2Platelets in inflammation and atherogenesisA novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and functionTargeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasisThe integrin alpha2beta1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-kB translocation and PDGF productionG6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2Renal cells activate the platelet receptor CLEC-2 through podoplaninInvolvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.RhoG protein regulates glycoprotein VI-Fc receptor γ-chain complex-mediated platelet activation and thrombus formationCLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development.Critical Role for an acidic amino acid region in platelet signaling by the HemITAM (hemi-immunoreceptor tyrosine-based activation motif) containing receptor CLEC-2 (C-type lectin receptor-2).Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells.Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber.A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif proteinPodoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skinPlatelet 12-LOX is essential for FcγRIIa-mediated platelet activation.The N-terminal SH2 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets.Targeted downregulation of platelet CLEC-2 occurs through Syk-independent internalization.Anti-miR-148a regulates platelet FcγRIIA signaling and decreases thrombosis in vivo in mice.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.The lymphatic system in health and disease.CLEC-2 expression is maintained on activated platelets and on platelet microparticles.Platelets and cancer: a casual or causal relationship: revisited.CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo.GPVI potentiation of platelet activation by thrombin and adhesion molecules independent of Src kinases and Syk.Phosphoproteomic analysis of platelets activated by pro-thrombotic oxidized phospholipids and thrombin.Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis.
P2860
Q24320164-AF0D99D8-2074-43AC-AFF0-7DACC6973F9FQ24652041-8D614F7C-5376-462F-A4FD-C2A52F060840Q24654154-1C49D141-BF92-4776-80A8-EFF5798ABFFAQ24657449-CB88A10A-2DDB-487B-B177-99E692D254F2Q24673797-5458BD6D-3812-4B27-A174-260B56F1293BQ24675771-248132F9-130B-4B91-BBB6-3A4322804A6AQ26747539-356664F0-4D4B-4A99-BF6A-22D471E01942Q26801407-7223D957-F9BE-4443-A463-35A364337178Q27001566-D5B777C2-E34E-45E2-85B1-99C4F2AB6F2BQ27025414-A79528AA-F38F-4B22-B880-258909025821Q27342857-A663F587-D10C-4465-B19D-EF3FE5BF284FQ28069805-BFAA3662-29DD-4429-9809-20965AE7520BQ28085020-52A0AD10-7627-49F2-B300-BEF5F4ACD312Q28115628-AB79DF1E-AE56-407F-BBE6-E8E1213D0232Q28600973-34C01834-AABC-44C3-8638-8A1E089826DAQ28771350-588C2574-8C62-4F14-A2A0-68C762E41865Q29347516-481A3BE5-426F-415A-A050-E26ED2B56337Q29347557-39E7D06F-13E5-4620-9601-9543F48D72C9Q30032296-9EB3826F-BE59-4E7F-B2FB-98C6B6FE2870Q30409434-EDF3BD48-B018-42D1-A0BA-706F33D27888Q30514065-73CC3674-B4EA-4BF9-8087-24254AF54920Q30583136-B05DF39E-B7B9-40EB-9965-F32E13562319Q30611441-9BBEE982-245C-4A24-841E-B51541371BF4Q31133789-F7E79CF1-F3AD-426E-9265-33C4CA760173Q32177061-61AE0089-B387-4FF0-8CC5-2350D97996B7Q33267507-2276C488-297D-4BD2-A8E5-1FCFDB999D2AQ33391455-890B112A-FC12-46A7-BD99-BA2BCF8CE1B5Q33416935-506FB3EB-FAFC-4032-B0CD-7B7F446E6BA7Q33418444-C7FF04CD-A44A-453C-B158-E4C7FC5077F3Q33421358-14EB5FE2-3381-41B4-BC0E-BC2C46944D2EQ33427174-42B9E6B4-358E-4AB4-8EE5-E9039F0243F0Q33863833-39003878-9B3C-4029-9C12-1153DBAF92CAQ33947226-E484AB40-BC38-4DEA-B990-CCFC7FDF1605Q34015299-9E59A41C-EA04-4B49-BB0E-162469B9A3B0Q34284335-C778E1B8-91E1-4855-8FA6-6DD483A42216Q34294719-E9B73493-5533-4255-9E3A-1A7F4F82B4ABQ34318501-779EF46C-A137-455B-B1A0-434D5FC7E492Q34343573-205B392D-C240-4101-8B41-E2F0710FEC02Q34396409-71900F08-7605-44AA-BCC9-D27BBF7BA461Q34522088-370BB20E-9259-4222-AFB7-AE61F51A5784
P2860
A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@ast
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@en
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@nl
type
label
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@ast
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@en
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@nl
prefLabel
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@ast
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@en
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2.
@nl
P2093
P50
P1433
P1476
A novel Syk-dependent mechanis ...... C-type lectin receptor CLEC-2
@en
P2093
Andrew C Pearce
Edina Schweighoffer
Gavin D Laing
Gemma L J Fuller
Johannes A Eble
Katsue Suzuki-Inoue
Nicole Zitzmann
Osamu Inoue
R David G Theakston
Sascha C Hughan
P304
P356
10.1182/BLOOD-2005-05-1994
P407
P577
2005-09-20T00:00:00Z